Natera Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Natera stock.
View analyst ratings for Natera or view top-rated stocks.

8 Wall Street analysts have issued 12-month price targets for Natera's shares. Their NTRA stock forecasts range from $54.00 to $139.00. On average, they predict Natera's stock price to reach $91.40 in the next twelve months. This suggests a possible upside of 147.5% from the stock's current price.
View analysts' price targets for Natera or view top-rated stocks among Wall Street analysts.

Natera's stock was trading at $93.39 at the beginning of 2022. Since then, NTRA stock has decreased by 60.5% and is now trading at $36.93.
View the best growth stocks for 2022 here.

Natera is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Natera.

Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings results on Thursday, May, 5th. The medical research company reported ($1.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.05. The medical research company earned $194.13 million during the quarter, compared to analyst estimates of $176.61 million. Natera had a negative net margin of 81.90% and a negative trailing twelve-month return on equity of 96.99%. Natera's revenue for the quarter was up 27.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.74) earnings per share.
View Natera's earnings history.

Natera updated its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $790.00 million-$810.00 million, compared to the consensus revenue estimate of $779.92 million.

158 employees have rated Natera CEO Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among Natera's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Natera include Exact Sciences (EXAS), Guardant Health (GH), Elekta AB (publ) (EKTAY), Fulgent Genetics (FLGT), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Invitae (NVTA), Viridian Therapeutics (VRDN), Burning Rock Biotech (BNR), DermTech (DMTK), Progenity (PROG), Personalis (PSNL) and Genetron (GTH).
View all of NTRA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTRA stock can currently be purchased for approximately $36.93.

Natera (NASDAQ:NTRA) has a market capitalization of $3.56 billion and generates $625.49 million in revenue each year. The medical research company earns $-471.72 million in net income (profit) each year or ($5.880010) on an earnings per share basis.

Natera employs 2,670 workers across the globe.

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for Natera is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.